HIV-1 Vif Adaptation to Human APOBEC3H Haplotypes

Slides:



Advertisements
Similar presentations
Volume 16, Issue 3, Pages (March 2008)
Advertisements

Volume 6, Issue 4, Pages (October 2000)
A Combinatorial CRISPR-Cas9 Attack on HIV-1 DNA Extinguishes All Infectious Provirus in Infected T Cell Cultures  Gang Wang, Na Zhao, Ben Berkhout, Atze.
Molecular Therapy - Nucleic Acids
Volume 14, Issue 1, Pages (July 2013)
Volume 15, Issue 2, Pages (February 2014)
Volume 28, Issue 3, Pages (November 2007)
The Interferon-Inducible MxB Protein Inhibits HIV-1 Infection
Volume 12, Issue 4, Pages (October 2012)
Volume 13, Issue 2, Pages (February 2013)
Volume 122, Issue 4, Pages (August 2005)
The F12-Vif derivative Chim3 inhibits HIV-1 replication in CD4+ T lymphocytes and CD34+-derived macrophages by blocking HIV-1 DNA integration by Simona.
Dynamins Are Forever: MxB Inhibits HIV-1
Volume 2, Issue 4, Pages (October 2000)
Identification of the HIV-1 Vif and Human APOBEC3G Protein Interface
Volume 10, Issue 6, Pages (December 2011)
Volume 9, Issue 2, Pages (February 2011)
John T. Arigo, Kristina L. Carroll, Jessica M. Ames, Jeffry L. Corden 
Volume 29, Issue 2, Pages (February 2008)
Sherilyn Grill, Valerie M. Tesmer, Jayakrishnan Nandakumar 
HIV-1 Vpu Mediates HLA-C Downregulation
Volume 15, Issue 4, Pages (April 2014)
Volume 22, Issue 3, Pages e5 (September 2017)
Volume 18, Issue 4, Pages (October 2015)
Volume 16, Issue 6, Pages (December 2014)
Volume 22, Issue 3, Pages e5 (September 2017)
Volume 4, Issue 3, Pages (September 2008)
Volume 16, Issue 3, Pages (September 2014)
Volume 20, Issue 3, Pages (September 2016)
Volume 69, Issue 1, Pages e9 (January 2018)
CDK11 in TREX/THOC Regulates HIV mRNA 3′ End Processing
Volume 23, Issue 1, Pages e7 (January 2018)
Molecular Therapy - Nucleic Acids
Alexander Falkenhagen, Sadhna Joshi  Molecular Therapy - Nucleic Acids 
Volume 17, Issue 4, Pages (April 2015)
Adam S. Dingens, Hugh K. Haddox, Julie Overbaugh, Jesse D. Bloom 
The Host Restriction Factor APOBEC3G and Retroviral Vif Protein Coevolve due to Ongoing Genetic Conflict  Alex A. Compton, Vanessa M. Hirsch, Michael.
Young-Hee Cho, Sang-Dong Yoo, Jen Sheen  Cell 
Volume 21, Issue 1, Pages (January 2017)
Gang Wang, Na Zhao, Ben Berkhout, Atze T Das  Molecular Therapy 
Volume 8, Issue 6, Pages (December 2010)
Volume 8, Issue 5, Pages (November 2010)
Volume 128, Issue 3, Pages (March 2005)
Volume 18, Issue 6, Pages (December 2015)
A Major Role for Capsule-Independent Phagocytosis-Inhibitory Mechanisms in Mammalian Infection by Cryptococcus neoformans  Cheryl D. Chun, Jessica C.S.
Volume 15, Issue 3, Pages (April 2016)
Volume 27, Issue 1, Pages (July 2007)
Analysis of GFP expression in gfp loss-of-function mutants.
Volume 19, Issue 4, Pages (April 2016)
Vaccinia Virus F11 Promotes Viral Spread by Acting as a PDZ-Containing Scaffolding Protein to Bind Myosin-9A and Inhibit RhoA Signaling  Yutaka Handa,
Volume 26, Issue 3, Pages (May 2007)
Diverse Herpesvirus MicroRNAs Target the Stress-Induced Immune Ligand MICB to Escape Recognition by Natural Killer Cells  Daphna Nachmani, Noam Stern-Ginossar,
Volume 9, Issue 1, Pages (January 2011)
Volume 9, Issue 2, Pages (February 2011)
Volume 41, Issue 2, Pages (January 2011)
An Inhibitory Activity in Human Cells Restricts the Function of an Avian-like Influenza Virus Polymerase  Andrew Mehle, Jennifer A. Doudna  Cell Host.
Position-Dependent Function for a Tandem MicroRNA miR-122-Binding Site Located in the Hepatitis C Virus RNA Genome  Catherine L. Jopling, Sylvia Schütz,
Volume 18, Issue 2, Pages (August 2015)
Volume 15, Issue 4, Pages (April 2014)
Volume 18, Issue 9, Pages (September 2011)
Volume 21, Issue 3, Pages (March 2017)
Michael U. Shiloh, Paolo Manzanillo, Jeffery S. Cox 
Regulation of KSHV Lytic Switch Protein Expression by a Virus-Encoded MicroRNA: An Evolutionary Adaptation that Fine-Tunes Lytic Reactivation  Priya Bellare,
Volume 28, Issue 5, Pages (May 2008)
Volume 14, Issue 1, Pages (July 2013)
Volume 14, Issue 15, Pages (August 2004)
A Splicing-Independent Function of SF2/ASF in MicroRNA Processing
Molecular Therapy - Nucleic Acids
CRISPR Immunological Memory Requires a Host Factor for Specificity
Volume 24, Issue 4, Pages e3 (October 2018)
Presentation transcript:

HIV-1 Vif Adaptation to Human APOBEC3H Haplotypes Marcel Ooms, Bonnie Brayton, Michael Letko, Susan M. Maio, Christopher D. Pilcher, Frederick M. Hecht, Jason D. Barbour, Viviana Simon  Cell Host & Microbe  Volume 14, Issue 4, Pages 411-421 (October 2013) DOI: 10.1016/j.chom.2013.09.006 Copyright © 2013 Elsevier Inc. Terms and Conditions

Figure 1 A3H Haplotypes Affect Viral Loads and Time to Treatment of HIV-Infected Patients in the OPTIONS Cohort (A) At least seven A3H haplotypes are described that differ at five amino acid positions (Wang et al., 2011). Only haplotypes I, II, and III are shown. The combination of both 15N (rs34522862) and 105R (rs139297) determine anti-HIV activity of a given A3H variant. (B) Seventy-six HIV-infected patients from the OPTIONS cohort at the University of California, San Francisco, were selected, and amino acid identity at position 105 was determined by SNP array (Illumina). Position 15 (rs34522862) was determined by PCR and sequencing of genomic DNA. (C) A3H haplotype frequencies of haplotypes I, II, and III. Fifty-six patients do not express any active A3H hapII, and 20 patients express at least one active A3H hapII. (D) Viral loads of inactive A3H and active A3H carriers were analyzed with a LME model SAS 9.2. Inactive A3H carriers have higher viral loads (+0.49 log10 c/mL HIV RNA, p < 0.0001) (see also Table S1). Cell Host & Microbe 2013 14, 411-421DOI: (10.1016/j.chom.2013.09.006) Copyright © 2013 Elsevier Inc. Terms and Conditions

Figure 2 Vif Adaption to Active A3H (A) Vif sequences were generated by RT-PCR and bulk sequencing of plasma viral RNA. Vif amino acid sequences of active and inactive A3H carriers were compared with VESPA (Rose and Korber, 2000), and the amino acid frequency ratios are plotted along the entire Vif sequence. Amino acid identities that differ more than the threshold are depicted using VisSPA software. (B) The indicated amino acids were cloned into LAI molecular clone (gray bars), and the WT LAI amino acids are shown as black bars. WT and mutants LAI plasmids were cotransfected with an active A3H hapII expression plasmid, and infectivity of produced viruses was tested on TZM-bl reporter cells. LAI WT without A3H hapII and LAI ΔVif with A3H hapII serve as negative and positive controls, respectively. Error bars represent standard deviations of three independent experiments. (C) LAI WT, ΔVif, and Vif 39V were cotransfected with all seven human APOBEC3 members. Infectivity of produced viruses was tested on TZM-bl reporter cells. Error bars represent standard deviations of three independent experiments (see also Figure S1). Cell Host & Microbe 2013 14, 411-421DOI: (10.1016/j.chom.2013.09.006) Copyright © 2013 Elsevier Inc. Terms and Conditions

Figure 3 A3H Counteraction of A3H Position 39 Variants and Patient Vifs (A) Different amino acids present at Vif position 39 in the OPTIONS cohort were cloned into LAI. WT and mutant Vif clones were cotransfected with A3H hapII. LAI WT 39F is indicated by black bars. Infectivity of produced viruses was tested on TZM-bl reporter cells. Error bars represent standard deviations of three experiments. (B) 293T cell lysates were analyzed by western blot and probed for HA, Vif, and tubulin. (C) Ten vif sequences were amplified from different cohort samples and tested for activity to counteract A3H hapII and rescue HIV infectivity. The amino acids at position 39, the patient numbers, and the patients’ A3H haplotypes are indicated. Error bars represent standard deviations of three experiments. (D) 293T cell lysates were analyzed by western blot and probed for HA, Vif, and tubulin. Cell Host & Microbe 2013 14, 411-421DOI: (10.1016/j.chom.2013.09.006) Copyright © 2013 Elsevier Inc. Terms and Conditions

Figure 4 A3H-Specific Vif Mutant HIV Replication in T Cell Lines (A) 293T-produced LAI WT and 11 Vif 39 mutant viruses were used to infect permissive MT4 T cells (no APOBEC3 expression) and permissive MT2 T cells (express all APOBEC3 members and inactive A3H hapI and hapIII). Clarified supernatants were harvested every 2 days, and infectivity was determined by a TZM-bl infectivity assay. (B) SupT1 cell lines transduced with empty, A3G, or A3H hapII expression plasmids (Hultquist et al., 2011) were infected with LAI WT 39F, 39V, 39I, and 39Y, and supernatants were harvested each day and tested for infectivity using a TZM-bl infectivity assay. (C) A3H hapII-expressing SupT1 T cells were infected in triplicate with three viruses encoding A3H-defective Vifs (39I, 39V, and 39E; each codon is indicated). Cultures were maintained until the appearance of syncytia and cell death (days of breakthrough are indicated with circled numbers). Vifs were sequenced, and the resulting Vif adaptations are indicated. Cell Host & Microbe 2013 14, 411-421DOI: (10.1016/j.chom.2013.09.006) Copyright © 2013 Elsevier Inc. Terms and Conditions

Figure 5 A3H-Specific Vif Mutant HIV Replication in PBMCs PBMCs from five anonymous donors (three homozygous for A3H hapI, donors 1–3; and two homozygous for A3H hapII, donors 4 and 5) were infected with the indicated viruses. Clarified supernatants were harvested every 2 days, and infectivity was determined by a TZM-bl infectivity assay. Error bars represent standard deviations of two independent infections. Cell Host & Microbe 2013 14, 411-421DOI: (10.1016/j.chom.2013.09.006) Copyright © 2013 Elsevier Inc. Terms and Conditions

Figure 6 Endogenously Expressed A3H in Primary Cells Hypermutates HIV-1 Cellular DNA was extracted from the infected PBMCs of Figure 5B and used to amplify a 335 bp fragment in pol (excluding primers). The same fragment amplified using plasmid DNA served as a control for 454 induced sequencing errors. Between 3,313 and 9,440 sequences per sample were generated. APOBEC3-specific hypermutations in unique sequences were detected with Hypermut software (Rose and Korber, 2000). The software-generated results represent a black horizontal line for each unique sequence and small colored dashes indicating APOBEC3-specific G-to-A mutations (see also Figure S2). Cell Host & Microbe 2013 14, 411-421DOI: (10.1016/j.chom.2013.09.006) Copyright © 2013 Elsevier Inc. Terms and Conditions

Figure 7 Quantitative Analysis of APOBEC3-Induced Mutations in Primary Cells (A) 454 deep sequencing-generated unique sequences were analyzed with Hypermut software (Rose and Korber, 2000), and the results were plotted as number of mutations per unique sequence. APOBEC3-specific G-to-A mutations are indicated in gray, whereas all other mutations are shown in white. ∗∗∗p < 0.001 (unpaired t tests, Prism software). (B) Hypermut software results were plotted only for APOBEC3-specific G-to-A mutations per individual sequence. The specific dinucleotide contexts of each G-to-A mutation were shown with the indicated colors, with A3G-specific GG to AG in red and GA to AA mutations in blue. ∗∗∗p < 0.001 (unpaired t tests, Prism software). (C) Hypermut results were analyzed and shown as the number of sequences with the indicated number of either GG-to-AG (red) or GA-to-AA mutations (blue) per individual sequence. The number of sequences without GG-to-AG and GA-to-AA mutations are indicated by gray bars (see also Figure S3). Cell Host & Microbe 2013 14, 411-421DOI: (10.1016/j.chom.2013.09.006) Copyright © 2013 Elsevier Inc. Terms and Conditions